ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

Views:
1548
Likes:
7

Views:
1548
Likes:
7
Share:

Now Playing
Part 2 | Session 3 of 10
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis
Marianna Fontana

Up Next
4m 45s

Part 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction
Ankeet Bhatt
8m 47s

Part 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF
Domingo Figal
4m 53s

Part 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients
Niklas Dyrby Johansen
3m 56s

Part 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF
Ross Campbell
5m 11s

Part 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
Stephen J Greene
8m 22s

Part 2 | Session 9 Diagnosis in Heart Failure in Women
John GF Cleland
3m 50s

Part 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
Jawad Haider Butt

26m 30s

Part 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten

5m 48s

Part 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz

13m 32s

Part 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi

4m 3s

Part 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall

2m 45s

Part 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Jasper J Brugts

6m 54s

Part 2 | Session 2 REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Ahmad Masri

Average (ratings)

No ratings

Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

4 sessions
Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney	Watch now
The PARAGLIDE-HF Trial	Watch now
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi	Watch now
TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction	Watch now

Part 2

Expert Interviews

10 sessions
MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring	Watch now
REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy	Watch now
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis	Watch now
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction	Watch now
DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF	Watch now
NUDGE-FLU: Increasing Influenza Vaccination in HF Patients	Watch now
DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF	Watch now
TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure	Watch now
Diagnosis in Heart Failure in Women	Watch now
Dapagliflozin and Peripheral Arterial Disease in Heart Failure	Watch now

About the episode

We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).

APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1 to receive either intravenous patisiran or a placebo.

Interview Questions:
1. What is the importance of this study?
2. What is the mechanism of action of the study drug (patisiran)?
4. What was study design, outcome measures and patient population?
5. What are the findings to date? What conclusions can be made?
6. Are there any specific patient subgroups with cardiomyopathy for whom patisiran may be more or less effective?
7. What are the next steps?